GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants
Phase 1
Completed
- Conditions
- Hypertension, Pulmonary
- Interventions
- Drug: AMB new formulation (1 mg)Drug: Reference AMB (5 mg)
- First Posted Date
- 2019-09-19
- Last Posted Date
- 2020-08-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 29
- Registration Number
- NCT04095286
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom
Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster
Phase 3
Completed
- Conditions
- Herpes Zoster
- Interventions
- Biological: Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A)Drug: Placebo
- First Posted Date
- 2019-09-16
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1430
- Registration Number
- NCT04091451
- Locations
- 🇬🇧
GSK Investigational Site, Trowbridge, United Kingdom
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma
Phase 1
Active, not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2019-09-16
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 118
- Registration Number
- NCT04091126
- Locations
- 🇬🇧
GSK Investigational Site, Southampton, United Kingdom
A Study to Test GlaxoSmithKline's (GSK) Respiratory Syncytial Virus RSV Candidate Vaccine's Safety and Immune Response in Japanese Older Adults
Phase 1
Completed
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Drug: PlaceboBiological: RSV_PreF3 Vaccine (GSK3844766A) adjuvanted with AS01B
- First Posted Date
- 2019-09-16
- Last Posted Date
- 2022-02-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 40
- Registration Number
- NCT04090658
- Locations
- 🇯🇵
GSK Investigational Site, Fukuoka, Japan
Pharmacokinetics of Gepotidacin Tablets in Adults and Adolescents Subjects
- First Posted Date
- 2019-09-06
- Last Posted Date
- 2020-09-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 34
- Registration Number
- NCT04079790
- Locations
- 🇺🇸
GSK Investigational Site, Las Vegas, Nevada, United States
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults
Phase 1
Completed
- Conditions
- Virus Diseases
- Interventions
- Biological: Lower dose formulation of RG SAM (CNE) vaccine (GSK3903133A)Biological: Medium dose formulation of RG SAM (CNE) vaccine (GSK3903133A)Biological: Low dose formulation of RG SAM (CNE) vaccine (GSK3903133A)Biological: Lowest dose formulation of RG SAM (CNE) vaccine (GSK3903133A)Drug: Saline PlaceboBiological: RabAvert
- First Posted Date
- 2019-08-20
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 160
- Registration Number
- NCT04062669
- Locations
- 🇺🇸
GSK Investigational Site, Rochester, New York, United States
Voltaren Emulgel 2% Acute Ankle Sprain Non Inferiority Study
Phase 3
Completed
- Conditions
- Pain
- Interventions
- First Posted Date
- 2019-08-12
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 313
- Registration Number
- NCT04052620
- Locations
- 🇨🇳
GSK Investigational Site, Shanghai, China
Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Subjects
Phase 1
Completed
- Conditions
- Cholestasis
- Interventions
- Drug: GSK2330672 (linerixibat)
- First Posted Date
- 2019-08-12
- Last Posted Date
- 2020-07-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 19
- Registration Number
- NCT04053023
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom
A Clinical Study Investigating the Efficacy of a Stannous Fluoride Dentifrice in Improving Gingival Health After Twice Daily Use for 3 Weeks
Phase 4
Completed
- Conditions
- Gingivitis
- Interventions
- Drug: Sensodyne Repair and ProtectDrug: Colgate Cavity Protection
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2020-11-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 130
- Registration Number
- NCT04050722
- Locations
- 🇺🇸
GSK Investigational Site, Las Vegas, Nevada, United States
Safety and Immunogenicity Study of GSK's Clostridium Difficile Vaccine 2904545A When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years
Phase 1
Completed
- Conditions
- Clostridium Infections
- Interventions
- Biological: C. difficile investigational vaccine based on the F2 antigen (GSK2904545A)Drug: PlaceboBiological: C. difficile investigational vaccine based on the F2 antigen (GSK2904545A) adjuvanted with AS01B
- First Posted Date
- 2019-07-19
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 140
- Registration Number
- NCT04026009
- Locations
- 🇧🇪
GSK Investigational Site, Gent, Belgium
© Copyright 2025. All Rights Reserved by MedPath